GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (FRA:2GH) » Definitions » Policyholder Funds

Merus NV (FRA:2GH) Policyholder Funds


View and export this data going back to 2018. Start your Free Trial

What is Merus NV Policyholder Funds?

Policyholder Funds only applies to insurance companies.


Merus NV Business Description

Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.